CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company focusing on oncology, announced that it will present the results obtained from an in-vivo study of aldoxorubicin at the American Association for Cancer Research Annual Meeting. CytRx Corporation (NASDAQ:CYTR), shares after opening at $3.59 moved to $3.60 on last trade day and at the end of the day closed at $3.39. Company price to sales ratio in past twelve months was calculated as 628.05 and price to cash ratio as 4.88. CytRx Corporation (NASDAQ:CYTR), showed a negative weekly performance of 2.87%.
MannKind corporation, the developer of the inhaled insulin Afrezza, suffered a minor drop in its shares as the FDA delayed the drug’s approval. According to Schaeffer’s Investment Research, MannKind plopped 8 percent, closing at $6.32. MannKind’s hearing with the FDA committee was originally schedule for April 15, 2014; but due to the recent information that MannKind had submitted to gain the drug’s approval, the FDA pushed the hearing date three months to July 15, 2014 to allow more time for a full review. MannKind Corporation (NASDAQ:MNKD), shares fell 8.06% in last trading session and ended the day on $6.32. MannKind Corporation (NASDAQ:MNKD), return on equity ratio is recorded as 153.90% and its return on assets is -78.70%. MannKind Corporation (NASDAQ:MNKD), yearly performance is 67.64%.
On April, 6, 2014, VIVUS, Inc. (NASDAQ:VVUS)’s shares declined 3.69% to $5.22. The company announced that management will present an overview of the company at the 13th Annual Needham Healthcare Conference on April 8, 2014, 3:40pm EDT at The Westin Grand Central Hotel, New York. VIVUS, Inc. (NASDAQ:VVUS), shares moved down 6.09% in last trading session and was closed at $5.09, while trading in range of $ 5.06 – 5.49. VIVUS, Inc. (NASDAQ:VVUS),year to date (YTD) performance is -43.94%.
On Apr, 4, 2014, GTx, Inc. (NASDAQ: GTXI) announced that Mitchell S. Steiner, its vice chairman and chief executive officer (CEO) and a co-founder of the company, is leaving GTx to pursue other business interests. Dr. Steiner has stepped down from his roles as CEO and vice chairman of the Board of Directors at the company effective Thursday April 3, 2014. GTx, Inc. (NASDAQ:GTXI), weekly performance is -7.84%. On last trading day company shares ended up $1.41. GTx, Inc. (NASDAQ:GTXI), distance from 50-day simple moving average (SMA50) is -18.18%. Analysts mean target Price for the company is $1.50.